Skip to content
Peptigraph home

CJC-1295 + Ipamorelin for Men: Studies and Label Warnings

Studies of CJC-1295 + Ipamorelin that enrolled only men, what they measured, and what is still unproven.

Medical review pendingGHRH + GHRP blendUpdated
Strongest evidence
Human RCT
Studies enrolling only men
3
in our evidence file (PubMed search, 11 Oct 2026)
FDA status
Not approved

Studies that enrolled only men

Each row is a study whose participants were described as men only. Results from one sex are not evidence for the other. Studies of animals and cells are not included. No study has tested CJC-1295 + Ipamorelin itself; rows are for each ingredient.

CJC-1295 + Ipamorelin studies that enrolled only men
StudyDesignPopulationDoseFirst outcome
Pharmaceutical research 1999, PMID 10496658Human RCTHealthy male volunteers; dose escalation, eight subjects at each of 5 dose levels4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kgGH release: A single episode of GH release peaked at 0.67 hours and fell to negligible levels at all doses.
Growth hormone & IGF research 2009, PMID 19386527Human uncontrolled trialHealthy young adult men; serum proteomics before and one week after a CJC-1295 injectionNot statedSerum protein changes: CJC analog injection changed the intensity of five serum protein spots; these are candidate biomarkers of GH/IGF-1 action, not clinical outcomes.
The Journal of clinical endocrinology and metabolism 2006, PMID 17018654Human uncontrolled trialHealthy men aged 20 to 40 years; GH sampled every 20 min overnight before and 1 wk after injection60 or 90 microg/kg CJC-1295 (single injection)GH secretion pattern: Trough GH rose 7.5-fold, mean GH 46% and IGF-I 45% one week after a single injection, with GH pulsatility preserved.

Peptides studied in men, compared

How strong is it?

Strongest evidence:Human RCT evidence, 4 of 4

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

What the cached men's-health summary covers

MedlinePlus frames men's health as including conditions that affect only men, with prostate cancer and low testosterone as its examples; neither is a measured outcome for either component of this blend.[10]

Studies that enrolled only men

An overnight sampling study in healthy men aged 20 to 40 gave a single injection of CJC-1295 at 60 or 90 microg/kg, a per-kg dose that is not converted here.[3]

In those men, trough GH rose 7.5-fold, mean GH rose 46% and IGF-I rose 45%, with the pulses unchanged in frequency and size.[3]

Serum proteomics in 11 healthy young men compared samples taken before CJC-1295 and a week after the injection.[2]

The ipamorelin pharmacokinetic trial enrolled eight healthy male subjects at each of 5 infusion rates between 4.21 and 140.45 nmol/kg over 15 minutes.[1]

What is not in the sources for men

Drugs@FDA returns no match for CJC-1295, so there is no label population text such as a hypogonadism indication to quote.[11]

The same lookup for ipamorelin also returns no match, so neither component has labelled male-specific warnings.[12]

The two randomised CJC-1295 trials enrolled healthy subjects aged 21 to 61 years; the abstract does not split results by sex.[13]

Other peptides people research for men

All peptides for men, compared

Common questions

Has CJC-1295 + Ipamorelin been studied in men?

3 studies we summarise enrolled only men. Results from one sex are not evidence for the other.

Is CJC-1295 + Ipamorelin approved for men?

No. CJC-1295 + Ipamorelin is not FDA approved for any use in men or anyone else.

What does CJC-1295 with ipamorelin do for men?

In the men-only sampling study, CJC-1295 increased trough and mean GH secretion and IGF-I production while pulsatility was preserved; the study tested CJC-1295 alone, not the blend.[3]

Is there a CJC-1295 ipamorelin dosage for men?

The only men-only CJC-1295 dosing in the sources is 60 or 90 microg/kg as a single injection in a research setting, which is a per-kg study dose and not a recommendation.[3]

More on CJC-1295 + Ipamorelin

Sources

  1. 1Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
  2. 2Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2009PMID 19386527Accessed 2 Oct 2026
  3. 3Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026
  4. 4PubMed search (CJC-1295): ("CJC-1295"[tiab] OR CJC1295[tiab]) (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  5. 5PubMed search (CJC-1295): ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  6. 6PubMed search (CJC-1295): ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  7. 7PubMed search (Ipamorelin): ipamorelin[tiab] (50 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search (Ipamorelin): ipamorelin[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search (Ipamorelin): ipamorelin[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  10. 10Official web pageOfficial web page · web page
  11. 11Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  12. 12Drugs@FDA (openFDA) search: active ingredient "ipamorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  13. 13Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026

Found an error? Report a correction.